首页 › 基金 › MPM BioImpact LLC › AKTS

MPM BioImpact LLC 对 AKTS 的持仓历史

AKTIS ONCOLOGY INC · 医疗保健

MPM BioImpact LLC 在 Q2 2026 的 13F 申报中披露持有 AKTS(AKTIS ONCOLOGY INC)4,835,872 股,市值约 US$155.9M,约占其申报组合的 9.50%,在其申报持仓中市值排名第 2 位。 MPM BioImpact LLC 最近 2 个申报季度中有 2 个季度披露了 AKTS 持仓,最早可追溯至 Q1 2026。

最新持仓 (Q2 2026)4.84M 股
申报持仓市值$155.86M
组合权重9.50%
首次申报Q1 2026
最近变动持有
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

MPM BioImpact LLC 对 AKTS 的持仓演变

MPM BioImpact LLC 于 Q1 2026 首次披露 AKTS 持仓:4,835,872 股(约 US$86.5M)。 该持仓在 Q2 2026 达到峰值 4,835,872 股,市值约 US$155.9M。 在 2 次申报中,MPM BioImpact LLC 的持股数量始终未变。 最近一期申报(Q2 2026)显示持股 4,835,872 股、市值约 US$155.9M。

逐季持仓明细

季度股数金额变化
Q1 2026 4.84M $86.51M 新进
Q2 2026 4.84M $155.86M 持有

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 AKTS 与 13F 数据

AKTS(AKTIS ONCOLOGY INC)属于医疗保健行业。我们追踪的基金中还有 121 只申报持有 AKTS,申报仓位最大的包括:EcoR1 Capital, LLC (US$155.5M), Blue Owl Capital Holdings LP (US$99.0M), RTW INVESTMENTS, LP (US$51.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 AKTS 的基金

查看 AKTS 的全部基金持有人 →

常见问题

How long has MPM BioImpact LLC held AKTS?

MPM BioImpact LLC has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is MPM BioImpact LLC's current position in AKTS?

As of Q2 2026, MPM BioImpact LLC holds 4.84M shares of AKTS (AKTIS ONCOLOGY INC), valued at $155.86M, representing 9.50% of its reported portfolio and ranking #2.

Has MPM BioImpact LLC been buying or selling AKTS?

In the latest 13F filing (Q2 2026), MPM BioImpact LLC held unchanged its position in AKTS. The position peaked in Q2 2026 at 4.84M shares.

Which other funds hold AKTS?

Other major institutional holders of AKTS include EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, RTW INVESTMENTS, LP, among 121 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.